Wall Street brokerages expect Assembly Biosciences (NASDAQ:ASMB) to post sales of $3.30 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Assembly Biosciences’ earnings. The lowest sales estimate is $3.00 million and the highest is $3.60 million. Assembly Biosciences reported sales of $2.36 million during the same quarter last year, which indicates a positive year-over-year growth rate of 39.8%. The firm is expected to report its next quarterly earnings results on Wednesday, August 8th.
According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $9.17 million for the current year, with estimates ranging from $3.60 million to $14.30 million. For the next year, analysts anticipate that the company will post sales of $28.90 million per share, with estimates ranging from $8.00 million to $63.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.11). Assembly Biosciences had a negative return on equity of 56.56% and a negative net margin of 379.22%. The business had revenue of $3.57 million for the quarter, compared to analyst estimates of $1.88 million.
A number of equities analysts have recently commented on ASMB shares. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Chardan Capital downgraded shares of Assembly Biosciences from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $35.00 to $50.00 in a research note on Friday, April 13th. BidaskClub downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 23rd. Jefferies Group raised their target price on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, ValuEngine upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $60.50.
Shares of Assembly Biosciences stock traded up $0.15 during trading hours on Tuesday, reaching $42.26. 95,700 shares of the company’s stock were exchanged, compared to its average volume of 189,595. Assembly Biosciences has a fifty-two week low of $41.64 and a fifty-two week high of $42.94.
In related news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $56.37, for a total value of $56,370.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $148,750 over the last quarter. 18.20% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the stock. Quantbot Technologies LP bought a new position in Assembly Biosciences in the 1st quarter valued at about $154,000. Jane Street Group LLC bought a new position in Assembly Biosciences in the 1st quarter valued at about $204,000. Teacher Retirement System of Texas bought a new position in Assembly Biosciences in the 4th quarter valued at about $242,000. MetLife Investment Advisors LLC bought a new position in Assembly Biosciences in the 4th quarter valued at about $326,000. Finally, Virtus Fund Advisers LLC bought a new position in Assembly Biosciences in the 4th quarter valued at about $361,000. Institutional investors and hedge funds own 77.21% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.